Managers’ transactions
June 28, 2023
Announcement no. 13
Managers’ transactions
In connection with the completion of BioPorto A/S’ rights issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them.
| 1. Details of the person discharging managerial responsibilities/person closely associated | |
| a) Name | Ejendomsselskabet Jano ApS |
| 2. Reason for the notification | |
| a) Position/status | Closely associated person to Jan Leth Christensen, member of the Board of Directors of BioPorto A/S |
| b) Initial notification/amendment | Initial notification |
| 3. Details of the issuer | |
| a) Name | BioPorto A/S |
| b) LEI | 5299004SWFL5JAN4W830 |
| 4. Details of the transaction(s) | |
| a) Description of the financial instrument, type of instrument Identification code | Shares ISIN code DK0062496394 merged with permanent ISIN code DK0011048619 on 27 June 2023 |
| b) Nature of the transaction | Purchase (subscription of shares in connection with rights issue) |
| c) Price(s) and volume(s) | Price: DKK 1.00, Volume: 8,000,000 |
d) Aggregated information
| N/A |
| e) Date of the transaction | 2023-06-23 5:30 a.m. UTC (7:30 a.m. CEST) |
| f) Place of the transaction | Nasdaq Copenhagen A/S, XCSE |
| 1. Details of the person discharging managerial responsibilities/person closely associated | |
| a) Name | John Patrick McDonough |
| 2. Reason for the notification | |
| a) Position/status | Chair of the Board of Directors of BioPorto A/S |
| b) Initial notification/amendment | Initial notification |
| 3. Details of the issuer | |
| a) Name | BioPorto A/S |
| b) LEI | 5299004SWFL5JAN4W830 |
| 4. Details of the transaction(s) | |
| a) Description of the financial instrument, type of instrument Identification code | Shares ISIN code DK0062496394 merged with permanent ISIN code DK0011048619 on 27 June 2023 |
| b) Nature of the transaction | Purchase (subscription of shares in connection with rights issue) |
| c) Price(s) and volume(s) | Price: DKK 1.00, Volume: 175,000 |
d) Aggregated information
| N/A |
| e) Date of the transaction | 2023-06-23 5:30 a.m. UTC (7:30 a.m. CEST) |
| f) Place of the transaction | Nasdaq Copenhagen A/S, XCSE |
| 1. Details of the person discharging managerial responsibilities/person closely associated | |
| a) Name | Maria Ninfa Medina Saunders |
| 2. Reason for the notification | |
| a) Position/status | Member of the Board of Directors of BioPorto A/S |
| b) Initial notification/amendment | Initial notification |
| 3. Details of the issuer | |
| a) Name | BioPorto A/S |
| b) LEI | 5299004SWFL5JAN4W830 |
| 4. Details of the transaction(s) | |
| a) Description of the financial instrument, type of instrument Identification code | Shares ISIN code DK0062496394 merged with permanent ISIN code DK0011048619 on 27 June 2023 |
| b) Nature of the transaction | Purchase (subscription of shares in connection with rights issue) |
| c) Price(s) and volume(s) | Price: DKK 1.00, Volume: 175,000 |
d) Aggregated information
| N/A |
| e) Date of the transaction | 2023-06-23 5:30 a.m. UTC (7:30 a.m. CEST) |
| f) Place of the transaction | Nasdaq Copenhagen A/S, XCSE |
| 1. Details of the person discharging managerial responsibilities/person closely associated | |
| a) Name | Anthony Paul Pare |
| 2. Reason for the notification | |
| a) Position/status | Chief Executive Officer of BioPorto A/S |
| b) Initial notification/amendment | Initial notification |
| 3. Details of the issuer | |
| a) Name | BioPorto A/S |
| b) LEI | 5299004SWFL5JAN4W830 |
| 4. Details of the transaction(s) | |
| a) Description of the financial instrument, type of instrument Identification code | Shares ISIN code DK0062496394 merged with permanent ISIN code DK0011048619 on 27 June 2023 |
| b) Nature of the transaction | Purchase (subscription of shares in connection with rights issue) |
| c) Price(s) and volume(s) | Price: DKK 1.00, Volume: 160,000 |
d) Aggregated information
| N/A |
| e) Date of the transaction | 2023-06-23 5:30 a.m. UTC (7:30 a.m. CEST) |
| f) Place of the transaction | Nasdaq Copenhagen A/S, XCSE |
| 1. Details of the person discharging managerial responsibilities/person closely associated | |
| a) Name | Neil Allan Goldman |
| 2. Reason for the notification | |
| a) Position/status | Chief Financial Officer and Executive Vice President of BioPorto A/S |
| b) Initial notification/amendment | Initial notification |
| 3. Details of the issuer | |
| a) Name | BioPorto A/S |
| b) LEI | 5299004SWFL5JAN4W830 |
| 4. Details of the transaction(s) | |
| a) Description of the financial instrument, type of instrument Identification code | Shares ISIN code DK0062496394 merged with permanent ISIN code DK0011048619 on 27 June 2023 |
| b) Nature of the transaction | Purchase (subscription of shares in connection with rights issue) |
| c) Price(s) and volume(s) | Price: DKK 1.00, Volume: 160,000 |
d) Aggregated information
| N/A |
| e) Date of the transaction | 2023-06-23 5:30 a.m. UTC (7:30 a.m. CEST) |
| f) Place of the transaction | Nasdaq Copenhagen A/S, XCSE |
For investor inquiries, please contact:
Tim Eriksen, EU Investor Relations, Zenith Advisory, +45 61 88 77 79, e-mail: [email protected]
About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
BioPorto’s flagship product, The NGAL TestTM, is designed to aid in the risk assessment of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The NGAL Test is CE marked and registered in several countries worldwide.
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR]. For more information visit www.bioporto.com.
Attachment
